Skip to main content
Back
Watch Compare

Cartesian Therapeutics, Inc.

Data quality: 100%
RNAC
Nasdaq Manufacturing Chemicals
$6.25
▲ $0.10 (1.63%)
Mkt Cap: 165.68 M
Price
$6.25
Mkt Cap
165.68 M
Day Range
$5.93 — $6.32
52-Week Range
$5.60 — $15.57
Volume
93,972
Open $6.16
50D / 200D Avg
$6.98
10.42% below
50D / 200D Avg
$8.87
29.52% below

Quick Summary

Key Takeaways

Revenue declined -57.42% annually over 5 years
Negative free cash flow of -79.40 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 35.39%
Capital intensive — 194.99% of revenue goes to capex

Growth

Revenue Growth (5Y)
-57.42%
Below sector avg (1.82%)
Revenue (1Y)-92.81%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
N/A
ROIC-30.81%
Net Margin-4658.63%
Op. Margin-5127.10%

Safety

Debt / Equity
N/A
Current Ratio10.67
Interest CoverageN/A

Valuation

PE (TTM)
-1.27
Above sector avg (-1.47)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)
Metric Stock Sector Median
P/E -1.3 -1.5
P/B — 1.6
ROE % — -53.5
Net Margin % -4658.6 -41.5
Rev Growth 5Y % -57.4 1.8
D/E — 0.3

ETFs Holding This Stock

BBC logo BBC Virtus Biotech Clinical Trials ETF
1.01% weight
EES logo EES WisdomTree U.S. SmallCap Fund
0.01% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) -92.81% Revenue Growth (3Y) -67.20%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -57.42% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 2.80 M Net Income (TTM) -130.30 M
ROE N/A ROA -34.22%
Gross Margin N/A Operating Margin -5127.10%
Net Margin -4658.63% Free Cash Flow (TTM) -79.40 M
ROIC -30.81% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 10.67
Interest Coverage N/A Asset Turnover 0.01
Working Capital 133.46 M Tangible Book Value -84.01 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1.27 Forward P/E N/A
P/B Ratio N/A P/S Ratio 59.24
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -47.92%
Market Cap 165.68 M Enterprise Value 22.30 M
Per Share
EPS (Diluted TTM) -5.02 Revenue / Share 0.11
FCF / Share -3.00 OCF / Share -2.79
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 194.99% FCF Conversion 60.93%
SBC-Adj. FCF -89.47 M Growth Momentum -35.39

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 2.80 M 38.91 M 26.00 M 110.78 M 85.08 M
Net Income -130.30 M -77.42 M -219.71 M 35.38 M -25.69 M
EPS (Diluted) -5.02 -4.49 -1.66 0.10 -0.22
Gross Profit — — — — —
Operating Income -143.41 M -43.90 M -86.42 M 14.54 M -4.60 M
EBITDA — — — — —
R&D Expenses 58.03 M 45.11 M 71.84 M 72.38 M 68.74 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense — 0.0 2.83 M 3.03 M 2.84 M
Income Tax -9.19 M 287,000.0 -19.00 M -609,000.0 15.97 M

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 296.41 M 435.02 M 305.05 M 165.89 M 159.88 M
Total Liabilities 422.65 M 441.83 M 444.68 M 72.06 M 137.36 M
Shareholders' Equity -126.24 M -6.80 M -440.18 M 93.83 M 22.52 M
Total Debt — — — — —
Cash & Equivalents 125.14 M 212.61 M 76.91 M 106.44 M 114.06 M
Current Assets 129.28 M 216.63 M 90.73 M 148.14 M 144.44 M
Current Liabilities 14.94 M 22.98 M 68.21 M 25.08 M 72.25 M